Q3 2025 13F Holders as of 30 Sep 2025
-
Type / Class
-
Equity / COM
-
Total 13F shares
-
13,927,352
-
Share change
-
+2,010,323
-
Total reported value
-
$30,914,125
-
Put/Call ratio
-
400%
-
Price per share
-
$2.22
-
Number of holders
-
76
-
Value change
-
+$4,618,112
-
Number of buys
-
32
-
Number of sells
-
24
Institutional Holders of Protalix BioTherapeutics, Inc. - COM (PLX) as of Q3 2025
As of 30 Sep 2025,
Protalix BioTherapeutics, Inc. - COM (PLX) was held by
76 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
13,927,352 shares.
The largest 10 holders included
BlackRock, Inc., Opaleye Management Inc., RENAISSANCE TECHNOLOGIES LLC, NORTHERN TRUST CORP, GEODE CAPITAL MANAGEMENT, LLC, Stratos Wealth Partners, LTD., STATE STREET CORP, VANGUARD GROUP INC, Connor, Clark & Lunn Investment Management Ltd., and UBS Group AG.
This page lists
76
institutional shareholders reporting positions in this security
for the Q3 2025 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.